个性化医学与高血压治疗。
Personalized Medicine and the Treatment of Hypertension.
机构信息
CardioVascular Research New Brunswick, Saint John Regional Hospital, HHN, Saint John, Canada.
IMPART Investigator Team Canada, Saint John, New Brunswick, Canada.
出版信息
Curr Hypertens Rep. 2019 Feb 12;21(2):13. doi: 10.1007/s11906-019-0921-3.
Abstract
PURPOSE OF REVIEW
The purpose of this review is to discuss the implications of personalized medicine for the treatment of hypertension, including resistant hypertension.
RECENT FINDINGS
We suggest a framework for the personalized treatment of hypertension based on the concept of a trade-off between simplicity and personalization. This framework is based on treatment strategies classified as low, medium, or high information burden personalization approaches. The extent to which a higher information burden is justified depends on the clinical scenario, particularly the ease with which the blood pressure can be controlled. A one-size-fits-many treatment strategy for hypertension is efficacious for most people; however, a more personalized approach could be useful in patients with subtypes of hypertension that do not respond as expected to treatment. Clinicians seeing patients with unusual hypertension phenotypes should be familiar with emerging trends in personalized treatment of hypertension.
摘要
目的综述
本文讨论了个性化医学对高血压治疗（包括难治性高血压）的影响。
最近的发现
我们根据简单化和个体化之间权衡取舍的概念，提出了一个高血压个体化治疗的框架。该框架基于治疗策略分类，包括低、中、高信息负担的个体化方法。更高的信息负担是否合理取决于临床情况，尤其是血压控制的难易程度。一种适合大多数人的高血压一刀切治疗策略是有效的；然而，对于那些对治疗反应不如预期的高血压亚类患者，更个性化的方法可能会有用。临床医生在治疗不常见的高血压表型患者时，应熟悉高血压个体化治疗的新兴趋势。
相似文献
1
Personalized Medicine and the Treatment of Hypertension.个性化医学与高血压治疗。
Curr Hypertens Rep. 2019 Feb 12;21(2):13. doi: 10.1007/s11906-019-0921-3.
2
Natural selection and local adaptation of blood pressure regulation and their perspectives on precision medicine in hypertension.血压调节的自然选择与局部适应性及其对高血压精准医学的启示
Hereditas. 2019 Jan 7;156:1. doi: 10.1186/s41065-019-0080-1. eCollection 2019.
3
Hypertension pharmacogenomics: in search of personalized treatment approaches.高血压药物基因组学：探寻个性化治疗方法。
Nat Rev Nephrol. 2016 Feb;12(2):110-22. doi: 10.1038/nrneph.2015.176. Epub 2015 Nov 23.
4
Personalized medicine-a modern approach for the diagnosis and management of hypertension.个性化医疗——高血压诊断与管理的现代方法。
Clin Sci (Lond). 2017 Nov 6;131(22):2671-2685. doi: 10.1042/CS20160407. Print 2017 Nov 15.
5
Riboflavin, MTHFR genotype and blood pressure: A personalized approach to prevention and treatment of hypertension.核黄素、MTHFR 基因型与血压：高血压预防与治疗的个体化策略。
Mol Aspects Med. 2017 Feb;53:2-9. doi: 10.1016/j.mam.2016.10.002. Epub 2016 Oct 6.
6
Gene-environment interactions of selected pharmacogenes in arterial hypertension.选定的药物代谢基因在动脉高血压中的基因-环境相互作用。
Expert Rev Clin Pharmacol. 2012 Nov;5(6):677-86. doi: 10.1586/ecp.12.58.
7
Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies.计算与药物基因组学在高血压治疗中的研究进展：合理药物设计与优化策略。
Curr Drug Targets. 2020;21(1):18-33. doi: 10.2174/1389450120666190808101356.
8
Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.用于个体化抗高血压和慢性肾病治疗的基因分型检测的分析有效性。
Pharmacogenet Genomics. 2019 Jan;29(1):18-22. doi: 10.1097/FPC.0000000000000361.
9
ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.血管紧张素转换酶（ACE）表型分析作为使用ACE抑制剂进行个体化治疗的指南。
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):374-386. doi: 10.1177/1074248416686188. Epub 2017 Jan 10.
10
Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?药物遗传学是否使我们更接近于高血压初始药物治疗的“个体化医学”？
Curr Opin Cardiol. 2009 Jul;24(4):333-9. doi: 10.1097/HCO.0b013e32832c58ba.
引用本文的文献
1
Applications, Challenges, and Future Perspectives of Artificial Intelligence in Psychopharmacology, Psychological Disorders and Physiological Psychology: A Comprehensive Review.人工智能在精神药理学、心理障碍和生理心理学中的应用、挑战及未来展望：综述
J Pharm Bioallied Sci. 2025 May;17(Suppl 1):S229-S233. doi: 10.4103/jpbs.jpbs_1765_24. Epub 2025 Apr 29.
2
Vision transformer-based stratification of pre/diabetic and pre/hypertensive patients from retinal photographs for 3PM applications.基于视觉变换器的视网膜照片中糖尿病前期/糖尿病患者及高血压前期/高血压患者分层，用于下午3点的应用。
EPMA J. 2025 May 20;16(2):519-533. doi: 10.1007/s13167-025-00412-9. eCollection 2025 Jun.
3
Factors associated with suboptimal adherence to antihypertensive medication: Cross-sectional study using nationally representative databases.与降压药物依从性欠佳相关的因素：使用全国代表性数据库的横断面研究。
Heliyon. 2024 Sep 26;10(19):e38531. doi: 10.1016/j.heliyon.2024.e38531. eCollection 2024 Oct 15.
4
Heterogeneity in response to treatment across tinnitus phenotypes.治疗反应在耳鸣表型间的异质性。
Sci Rep. 2024 Jan 24;14(1):2111. doi: 10.1038/s41598-024-52651-x.
5
CURATE.AI-assisted dose titration for anti-hypertensive personalized therapy: study protocol for a multi-arm, randomized, pilot feasibility trial using CURATE.AI (CURATE.AI ADAPT trial).CURATE.AI辅助的抗高血压个性化治疗剂量滴定：一项使用CURATE.AI的多组、随机、试点可行性试验的研究方案（CURATE.AI ADAPT试验）
Eur Heart J Digit Health. 2023 Oct 24;5(1):41-49. doi: 10.1093/ehjdh/ztad063. eCollection 2024 Jan.
6
Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management.用于预防心血管疾病的复方制剂疗法及用于管理高血压的联合药物疗法。
J Clin Med. 2023 Nov 22;12(23):7226. doi: 10.3390/jcm12237226.
7
Personalized Medicine in Kidney Disease.肾脏病中的个性化医疗
J Pers Med. 2023 Oct 16;13(10):1501. doi: 10.3390/jpm13101501.
8
Study on the application effect of the family doctor contract service mode of 'basic package+personalised package' in elderly hypertension management in Chengdu, China: a retrospective observational study.中国成都“基础包+个性化包”家庭医生签约服务模式在老年高血压管理中的应用效果研究：回顾性观察研究。
BMJ Open. 2023 May 16;13(5):e064908. doi: 10.1136/bmjopen-2022-064908.
9
The link between immunity and hypertension in the kidney and heart.肾脏和心脏中免疫与高血压之间的联系。
Front Cardiovasc Med. 2023 Mar 9;10:1129384. doi: 10.3389/fcvm.2023.1129384. eCollection 2023.
10
Personalized hypertension treatment recommendations by a data-driven model.基于数据驱动模型的个体化高血压治疗推荐。
BMC Med Inform Decis Mak. 2023 Mar 1;23(1):44. doi: 10.1186/s12911-023-02137-z.
本文引用的文献
1
A data-zone scoring system to assess the generalizability of clinical trial results to individual patients.一种数据分区评分系统，用于评估临床试验结果对个体患者的可推广性。
Eur J Prev Cardiol. 2019 Apr;26(6):569-575. doi: 10.1177/2047487318815967. Epub 2018 Nov 26.
2
Primary Aldosteronism: Practical Approach to Diagnosis and Management.原发性醛固酮增多症：诊断与治疗的实用方法。
Circulation. 2018 Aug 21;138(8):823-835. doi: 10.1161/CIRCULATIONAHA.118.033597.
3
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.耐药性高血压：检测、评估与管理：美国心脏协会科学声明。
Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.
4
Human Urinary mRNA as a Biomarker of Cardiovascular Disease.人尿 mRNA 作为心血管疾病的生物标志物。
Circ Genom Precis Med. 2018 Sep;11(9):e002213. doi: 10.1161/CIRCGEN.118.002213.
5
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.预测 250 种死因的预期寿命、损失的生命年数以及全因和特定死因死亡率：2016-2040 年 195 个国家和地区的参考和替代情景。
Lancet. 2018 Nov 10;392(10159):2052-2090. doi: 10.1016/S0140-6736(18)31694-5. Epub 2018 Oct 16.
6
Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.固定低剂量三联抗高血压药物与常规护理治疗斯里兰卡轻中度高血压患者的血压控制：一项随机临床试验。
JAMA. 2018 Aug 14;320(6):566-579. doi: 10.1001/jama.2018.10359.
7
Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study.多层面干预高血压患者的集群随机试验的原理和设计：心脏结局预防和评估 4（HOPE-4）研究。
Am Heart J. 2018 Sep;203:57-66. doi: 10.1016/j.ahj.2018.06.004. Epub 2018 Jun 22.
8
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.血压特征基因与噻嗪类利尿剂降压反应：PEAR 和 PEAR-2 研究结果。
BMC Med Genomics. 2018 Jun 20;11(1):55. doi: 10.1186/s12920-018-0370-x.
9
Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs.常用抗高血压药物不良药物事件自发报告中的性别差异。
Eur J Clin Pharmacol. 2018 Sep;74(9):1165-1173. doi: 10.1007/s00228-018-2480-y. Epub 2018 May 27.
10
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.血管内超声肾去神经术治疗高血压（RADIANCE-HTN SOLO）：一项多中心、国际、单盲、随机、假对照试验。
Lancet. 2018 Jun 9;391(10137):2335-2345. doi: 10.1016/S0140-6736(18)31082-1. Epub 2018 May 23.
Zotero 插件